Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

被引：0
|
作者：
Aljitawi, Omar S. [1 ]
McGuirk, Joseph P. [1 ]
机构：
[1] Univ Kansas, Med Ctr, Blood & Marrow Transplant Program, Kansas City, KS 66103 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
autologous; chemotherapy; multiple myeloma; preparative regimen; review; transplant; STEM-CELL TRANSPLANTATION; CONDITIONING REGIMEN; PHASE-II; RANDOMIZED-TRIAL; ALLOGENEIC TRANSPLANTATION; INTERGROUPE FRANCOPHONE; STANDARD CHEMOTHERAPY; 200 MG/M(2); MELPHALAN; CYCLOPHOSPHAMIDE;
D O I：
10.2217/CER.11.11
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
High-dose chemotherapy and autologous stem cell transplantation remains a standard procedure in relatively young and selected older patients with multiple myeloma. High-dose melphalan has remained the chemotherapeutic agent of choice based on earlier prospective randomized trials. Despite investigations involving different combinations of chemotherapeutics, radiation and novel agents with and without melphalan, none of these alternative preparative regimens have demonstrated superiority to high-dose melphalan used as a single agent in multiple published studies. In this article, we review the published literature regarding preparative regimens used in patients with multiple myeloma undergoing autologous stem cell transplantation.
引用
收藏
页码：57 / 70
页数：14
相关论文
共 50 条
  • [31] High-dose cyclophosphamide as an effective therapy for a patient with refractory multiple myeloma relapsing after autologous stem cell transplantation
    Yagisawa, K
    Aiba, A
    Momoi, A
    Tsukada, N
    Nikkuni, K
    Aoki, S
    Aizawa, Y
    INTERNAL MEDICINE, 2005, 44 (05) : 471 - 475
  • [32] Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Lacy, MQ
    Witzig, TE
    Lust, JA
    Greipp, PR
    Therneau, TM
    Kyle, RA
    Litzow, MR
    Gertz, MA
    BONE MARROW TRANSPLANTATION, 1999, 24 (05) : 497 - 503
  • [33] Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
    SV Rajkumar
    R Fonseca
    MQ Lacy
    TE Witzig
    JA Lust
    PR Greipp
    TM Therneau
    RA Kyle
    MR Litzow
    MA Gertz
    Bone Marrow Transplantation, 1999, 24 : 497 - 503
  • [34] Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma
    Malard, Florent
    Battipaglia, Giorgia
    Gaugler, Beatrice
    Siblany, Lama
    van de Wyngaert, Zoe
    Bonnin, Agnes
    Dulery, Remy
    Banet, Anne
    Stocker, Nicolas
    Ricard, Laure
    Brissot, Eolia
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2023, 58 (11) : 1275 - 1278
  • [35] High-dose treatment with autologous stem cell transplantation in multiple myeloma:: Past, present, and future
    Björkstrand, Bo
    Gahrton, Gösta
    SEMINARS IN HEMATOLOGY, 2007, 44 (04) : 227 - 233
  • [36] High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
    Lisenko, Katharina
    Sauer, Sandra
    Bruckner, Thomas
    Egerer, Gerlinde
    Goldschmidt, Hartmut
    Hillengass, Jens
    Schmier, Johann W.
    Shah, Sofia
    Witzens-Harig, Mathias
    Ho, Anthony D.
    Wuchter, Patrick
    BMC CANCER, 2017, 17
  • [37] High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
    Alexandra Gomez-Arteaga
    Tomer M. Mark
    Danielle Guarneri
    Paul J. Christos
    Usama Gergis
    June D. Greenberg
    Jingmei Hsu
    Sebastian A. Mayer
    Ruben Niesvizky
    Roger N. Pearse
    Adrienne A. Phillips
    Adriana Rossi
    Morton Coleman
    Koen van Besien
    Tsiporah B. Shore
    Bone Marrow Transplantation, 2019, 54 : 2027 - 2038
  • [38] HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA
    FERMAND, JP
    CHEVRET, S
    HENNEQUIN, C
    LEVY, Y
    GEROTA, J
    BENBUNAN, M
    SELIGMANN, M
    BROUET, JC
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1991, 33 (06): : 525 - 528
  • [39] High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
    Katharina Lisenko
    Sandra Sauer
    Thomas Bruckner
    Gerlinde Egerer
    Hartmut Goldschmidt
    Jens Hillengass
    Johann W. Schmier
    Sofia Shah
    Mathias Witzens-Harig
    Anthony D. Ho
    Patrick Wuchter
    BMC Cancer, 17
  • [40] HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RESISTANT MULTIPLE-MYELOMA
    BARLOGIE, B
    ALEXANIAN, R
    DICKE, KA
    ZAGARS, G
    SPITZER, G
    JAGANNATH, S
    HORWITZ, L
    BLOOD, 1987, 70 (03) : 869 - 872
12345